6VRC
Cryo-EM structure of Cas13(crRNA)
Summary for 6VRC
| Entry DOI | 10.2210/pdb6vrc/pdb |
| EMDB information | 21366 21367 |
| Descriptor | CRISPR-associated endoribonuclease Cas13a, RNA (51-MER) (2 entities in total) |
| Functional Keywords | crispr-cas system, cas13, immune system, typevi |
| Biological source | Listeria seeligeri serovar 1/2b (strain ATCC 35967 / DSM 20751 / CIP 100100 / SLCC 3954) More |
| Total number of polymer chains | 2 |
| Total formula weight | 152344.68 |
| Authors | Jia, N.,Meeske, A.J.,Marraffini, L.A.,Patel, D.J. (deposition date: 2020-02-07, release date: 2020-06-10, Last modification date: 2024-03-06) |
| Primary citation | Meeske, A.J.,Jia, N.,Cassel, A.K.,Kozlova, A.,Liao, J.,Wiedmann, M.,Patel, D.J.,Marraffini, L.A. A phage-encoded anti-CRISPR enables complete evasion of type VI-A CRISPR-Cas immunity. Science, 369:54-59, 2020 Cited by PubMed Abstract: The CRISPR RNA (crRNA)-guided nuclease Cas13 recognizes complementary viral transcripts to trigger the degradation of both host and viral RNA during the type VI CRISPR-Cas antiviral response. However, how viruses can counteract this immunity is not known. We describe a listeriaphage (ϕLS46) encoding an anti-CRISPR protein (AcrVIA1) that inactivates the type VI-A CRISPR system of Using genetics, biochemistry, and structural biology, we found that AcrVIA1 interacts with the guide-exposed face of Cas13a, preventing access to the target RNA and the conformational changes required for nuclease activation. Unlike inhibitors of DNA-cleaving Cas nucleases, which cause limited immunosuppression and require multiple infections to bypass CRISPR defenses, a single dose of AcrVIA1 delivered by an individual virion completely dismantles type VI-A CRISPR-mediated immunity. PubMed: 32467331DOI: 10.1126/science.abb6151 PDB entries with the same primary citation |
| Experimental method | ELECTRON MICROSCOPY (3.2 Å) |
Structure validation
Download full validation report
